RxDoctor Payments Data

Cary Peterson

Family Medicine · Erie, PANPI 1982831558

Payments from drug & device makers

$3,197in general payments, 2019–2025

Across 150 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$448
  • Braeburn Inc.$332
  • Pfizer$326
  • Novo Nordisk$262
  • Biohaven Pharmaceuticals, Inc.$245
  • Lilly USA, LLC$199
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,197100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,197 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$54,196
Medicare patients
116
Services billed
680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$65,031
JardianceEmpagliflozin44$55,310
MounjaroTirzepatide39$40,712
EliquisApixaban21$33,851
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$30,512
JanuviaSitagliptin Phosphate16$24,434
TrulicityDulaglutide23$22,164
XareltoRivaroxaban16$21,274
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$9,242
Incruse ElliptaUmeclidinium Bromide17$5,925
TrintellixVortioxetine Hydrobromide11$4,929
Atorvastatin Calcium440$4,596
Gabapentin150$3,373
Tizanidine Hcl18$3,307
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$3,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$262$65,03171 claims
Lilly USA, LLCMounjaro, Trulicity$199$62,87562 claims
Boehringer IngelheimJardiance$109$55,31044 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$177$45,67968 claims
PfizerEliquis$326$33,85121 claims
MerckJanuvia$76$24,43416 claims
Johnson & JohnsonXarelto$34$21,27416 claims
AbbVieSynthroid$448$2,98228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →